Stay updated on Cabozantinib in Recurrent/ Metastatic Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in Recurrent/ Metastatic Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib in Recurrent/ Metastatic Endometrial Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedLocations section updated to reflect changes in trial sites, adding and removing site entries across the U.S. and Canada (California, Illinois, Indiana, Michigan, Pennsylvania, Alberta, Ontario). The revision tag shows v3.3.3.SummaryDifference0.7%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedPublications section now notes that items are automatically filled from PubMed. The revision version is updated to v3.3.2, replacing the previous PubMed description (v3.2.0).SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the government funding notice about NIH operating status, an administrative item that does not affect trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check70 days agoChange DetectedThe study page shows an updated last update date and a Completed status, while core details—eligibility criteria, Primary/Secondary outcomes, and locations—remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check91 days agoChange DetectedUpdated page with newer cancer staging terms, location/center details, dates, and revision version; older staging terms, location, date, and revision removed.SummaryDifference4%

- Check98 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib in Recurrent/ Metastatic Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Recurrent/ Metastatic Endometrial Cancer Clinical Trial page.